Loading
Old version — revision 1
This is a fixed snapshot of Gene drives, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/gene-drive.md — the filesystem corpus, unchanged. Not an edit.
Genetic elements engineered to bias their own inheritance above the Mendelian half, allowing an introduced trait to spread through a wild population.
Gene drives are genetic elements that copy themselves into the matching chromosome in the germline, so that a heterozygous parent passes the element to far more than half of its offspring. An engineered drive can therefore spread through a wild population from a small release, in principle carrying a trait to fixation against natural selection. The idea long predates CRISPR–Cas9, but the ability to program a nuclease with an RNA guide is what made building one straightforward, and what turned a theoretical proposal into a governance problem.
A standard homing drive consists of a nuclease, a guide RNA that specifies a site in the host genome, and the whole cassette inserted at that same site. In a heterozygote, the drive-bearing chromosome expresses the nuclease, which cuts the corresponding site on the intact homologous chromosome. If the cell repairs that break by homologous recombination, it uses the drive-bearing chromosome as template and copies the entire cassette across. The organism, formerly heterozygous, is now homozygous, and every gamete carries the drive.
The two useful designs differ in what they carry. Population modification drives spread a cargo that makes the organism harmless — in mosquitoes, an effector that blocks development of the malaria parasite — while leaving the population intact. Population suppression drives target a gene required for female fertility or sex determination; the drive spreads while it is rare and heterozygous, and the population collapses as homozygotes accumulate. Suppression is more powerful and less reversible.
Why anyone is attempting thisMalaria kills roughly six hundred thousand people a year, most of them African children under five, and insecticide resistance has eroded the effectiveness of bed nets and spraying.1 A drive is one of very few proposals that would not require sustained delivery of anything to the households at risk.
The concept was worked out in theory a decade before anyone could build one, and the decisive change was not an insight about population genetics but the arrival of a nuclease that could be aimed at an arbitrary sequence.
The technical arc has been consistent: drives work in insects, resistance is the main obstacle, and careful target choice can defeat resistance in a cage. The unresolved questions are all about what happens outside one.
One feature of the field's history is unusual. The 2014 paper by Kevin Esvelt, George Church and colleagues that described CRISPR drives also argued for containment standards and public discussion before any drive was built, and was published alongside a policy piece to that effect. The technology was therefore proposed and criticised by the same people at the same time, an inversion of the sequence at the Asilomar Conference on Recombinant DNA four decades earlier, where the moratorium followed the capability.
The drive's own mechanism generates its principal failure mode. When the nuclease cuts the homologous chromosome, homologous recombination copies the drive across, but end joining instead produces a small insertion or deletion at the cut site. That altered sequence is no longer recognised by the guide RNA. If the resulting allele still works, it is a resistance allele that is immune to the drive and favoured by selection whenever the drive imposes a fitness cost — and suppression drives impose a very large one.
Two countermeasures have worked in the laboratory. One is to target a sequence so functionally constrained that almost any indel destroys the gene, so resistance alleles are themselves lethal or sterile. The other is multiplexing several guide RNAs against the same gene, so that resistance requires simultaneous escape at multiple sites. Neither has been tested against the standing genetic variation of a wild population, which is far larger than any cage contains.
No gene drive organism has been released anywhere as of 2026. The most advanced programme, Target Malaria, a not-for-profit research consortium working on Anopheles gambiae in West and East Africa, has followed a deliberately staged path: first a release of genetically modified sterile males that could not persist, then male-biasing strains, with a drive release contemplated only after regulatory and community processes conclude. The releases conducted so far involved no drive.
Two adjacent technologies are already deployed and are frequently confused with drives. Self-limiting modified male Aedes aegypti have been released at scale in Brazil and, in a smaller pilot, in the Florida Keys; they reduce local populations but disappear within generations and must be re-released. Mosquitoes carrying Wolbachia bacteria, which distort inheritance without any engineered nuclease, have been established in several cities and were associated with a large reduction in dengue incidence in a randomised trial in Indonesia.2 Both illustrate that population-level intervention is possible without a self-propagating edit.
In mammals, drives remain far weaker. A drive built in mice copied itself only in the female germline and at rates too low to spread, so proposals to control invasive rodents on islands have no working molecular basis yet.3 The gap between what is possible in an insect germline and in a mammalian one is a recurring theme in applied genetics, and it constrains conservation proposals as much as it constrains the edited proxy animals pursued under De-extinction by firms such as Colossal Biosciences.
Because a standard homing drive is designed to spread indefinitely, most current research effort goes into designs that do not.
The logic parallels the synthetic auxotrophy used for biocontainment in Genetic code expansion and recoding: rather than trusting physical barriers, the organism is engineered so that escape is self-defeating. The honest position is that reversibility here is a design intention rather than a demonstrated capability. Nothing engineered has yet been recalled from a wild population.
The ecological concerns are of three kinds: effects on species that eat or are pollinated by the target; spread of the construct into related species through hybridisation, which is a live issue in the Anopheles gambiae species complex; and the possibility that a suppression drive succeeds more completely or more widely than intended. The off-target problem takes an unusual form here, since a drive amplifies itself over generations and any unintended edit it carries travels with it.
Governance has settled into an uneasy pattern. A 2016 United States National Academies report endorsed continued research with staged testing rather than prohibition. Proposals for a global moratorium at the Convention on Biological Diversity were rejected in 2018 in favour of decisions calling for case-by-case risk assessment and for the free, prior and informed consent of indigenous peoples and local communities potentially affected. The World Health Organization has published a testing framework for genetically modified mosquitoes. None of these instruments is binding in the way that domestic biosafety law is, and a drive released anywhere will not respect the jurisdiction that authorised it — a structural problem shared with the concerns raised in Mirror life and, more distantly, in Dual-use research of concern.
The consent question has no clean answer. The population that must agree to a release is not the population that will be affected, since mosquitoes cross borders and generations — a problem formally similar to the objection that no future person can consent to Human germline editing, but at ecosystem scale. Frameworks developed for Governance of human genome editing in medicine assume an identifiable patient and do not transfer, and arguments from the Precautionary principle cut both ways when the status quo is a disease that kills hundreds of thousands of people annually. Drives are also a standard case in the Existential risk literature, less because a mosquito drive threatens humanity than because it is the first cheap technology whose intended behaviour is unbounded spread. Proposals for staged, reversible deployment are the clearest applied instance of Differential technological development in biology.
The technical questions that remain are ecological rather than molecular: how a drive behaves across a structured, seasonally fluctuating wild population with far more genetic variation than any cage, and whether modelling can be trusted before a release that cannot be undone. Field trials of any drive-carrying organism would be the first deliberate release of a self-propagating engineered element, and the decision is not principally a scientific one. Whether the first such release happens this decade depends less on the drive's performance in cages than on whether an African regulator, a national government and an affected community all decide, in that order, that the alternative is worse.
reportWorld Health Organization. World Malaria Report. Annual series; figures cited are from the 2024 edition.↩WHO malaria deaths are modelled estimates rather than counted deaths, and carry wide uncertainty intervals.
paperUtarini, A. et al. "Efficacy of Wolbachia-infected mosquito deployments for the control of dengue." New England Journal of Medicine, 2021.↩A cluster-randomised trial in Yogyakarta, Indonesia. Wolbachia is not a gene drive and involves no engineered nuclease.
paperGrunwald, H. A. et al. "Super-Mendelian inheritance mediated by CRISPR–Cas9 in the female mouse germline." Nature, 2019. ↩
paperNoble, C. et al. "Daisy-chain gene drives for the alteration of local populations." Proceedings of the National Academy of Sciences, 2019.↩The design is worked out in population-genetic models; the paper does not report a daisy-chain drive built in an organism.